Personalized Feedback for Distress Intolerant Smokers

Sponsor
University of Houston (Other)
Overall Status
Completed
CT.gov ID
NCT03918031
Collaborator
National Institute on Drug Abuse (NIDA) (NIH)
115
1
2
27.3
4.2

Study Details

Study Description

Brief Summary

This project will develop and refine a computer-delivered integrated Personalized Feedback Intervention (PFI) that directly addresses smoking and distress tolerance. The PFI will focus on feedback about smoking behavior, distress tolerance, and adaptive coping strategies.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: PFI for Smoking & Distress Tolerance
  • Behavioral: PFI for Smoking Only
N/A

Detailed Description

The primary goal of the research study is to investigate the efficacy of a brief, personalized computer-delivered transdiagnostic intervention (PFI) that addresses smoking and distress tolerance to reduce smoking, increase quit attempts, reduce perceived barriers to cessation, increase distress tolerance, reduce anxiety/depressive symptoms, and increase adaptive coping skills compared to a personalized feedback on smoking only control. To address this aim, the investigators will implement a randomized controlled trial that will employ a longitudinal experimental design and involve four stages: (a) phone-screener (pre-screener); (b) baseline appointment consisting of a pre-intervention assessment (eligibility), random assignment to a one-session computer-delivered intervention (Active PFI versus Control PFI with no personalized feedback on distress tolerance), and a post-intervention assessment; (c) 2-week follow-up; (d) 1-month follow-up. Assessments will include a multi-method approach, including biological, behavioral, and self-report methods.

Study Design

Study Type:
Interventional
Actual Enrollment :
115 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
If participant meets eligibility criteria, the participant will be randomly assigned to complete a one-session computer-delivered intervention: either (1) personalized feedback intervention on ability to handle discomfort and smoking or (2) personalized feedback intervention on smoking only.If participant meets eligibility criteria, the participant will be randomly assigned to complete a one-session computer-delivered intervention: either (1) personalized feedback intervention on ability to handle discomfort and smoking or (2) personalized feedback intervention on smoking only.
Masking:
Single (Participant)
Primary Purpose:
Treatment
Official Title:
Personalized Feedback for Distress Intolerant Smokers
Actual Study Start Date :
Jul 15, 2019
Actual Primary Completion Date :
Oct 24, 2021
Actual Study Completion Date :
Oct 24, 2021

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: PFI for Smoking & Distress Tolerance

A brief, one-session computer-delivered personalized feedback intervention (PFI) that addresses smoking and distress tolerance.

Behavioral: PFI for Smoking & Distress Tolerance
Personalized Feedback Intervention for smoking and distress tolerance.

Active Comparator: PFI for Smoking Only

A brief, one-session computer-delivered personalized feedback intervention (PFI) that addresses smoking only (no distress tolerance component).

Behavioral: PFI for Smoking Only
Personalized Feedback Intervention for smoking only (no distress tolerance component)

Outcome Measures

Primary Outcome Measures

  1. Rulers for Smoking Cessation [Assess change from baseline to 2-week and 1-month follow-up]

    The Rulers for Smoking Cessation asks participants to rate three rulers associated with motivation, confidence, and intention to quit smoking. Motivation is indexed by, "How important is stopping smoking to you (0 = Not important at all; 10 = Most important goal of my life)?" with a higher score indicating a better outcome. Confidence is indexed by, "How confident are you that you will quit smoking within the next month (0 = Not at all; 10 = 100% confident)?" with a higher score indicating a better outcome. Intention is indexed by, "How ready are you to quit smoking within the next month (0 = Not at all; 10 = 100% ready)?" with a higher score indicating a better outcome.

  2. Barriers to Cessation Scale [Assess change from baseline to 2-week and 1-month follow-up]

    The Barriers to Cessation Scale assesses 19-barriers, or specific stressors, associated with smoking cessation. Participants indicate, according to a 4-point Likert-style scale (0 = Not a barrier to 3 = Large barrier), the extent to which they identify with each of the barriers to cessation. Lower scores indicate a better outcome (range = 0 - 57).

  3. Smoking History Questionnaire [Assess change from baseline to 2-week and 1-month follow-up]

    The Smoking History Questionnaire is a self-report questionnaire used that will be used to assess smoking rate and number of quit attempts. This measure contains 30 items including open ended formats in which the individual will self-report their smoking rate per day and number of previous quit attempts. Lower reported smoking rate indicates a better outcome. Higher reported number of quit attempts indicates a better outcome.

  4. Distress Tolerance Scale [Assess change from baseline to 2-week and 1-month follow-up]

    The Distress Tolerance Scale is a self-report measure in which respondents indicate, on a 5-point Likert-type scale (1 = 'strongly agree' to 5 = 'strongly disagree'), the extent to which they believe they can experience and withstand distressing emotional states. All items are averaged to create a total mean score ranging from 1 to 5 with higher total scores indicating a better outcome.

  5. Mood and Anxiety Symptom Questionnaire-Short Form [Assess change from baseline to 2-week and 1-month follow-up]

    The Mood and Anxiety Symptom Questionnaire-Short Form will be used to assess anxiety/depressive symptoms. Participants indicate how much they have experienced each symptom on a 5-point Likert-type scale (1 = Not at all to 5 = Extremely). Specifically, the Anxious Arousal subscale will be used to measure anxiety and the Anhedonic Depression subscale will be used to measure depression. The Anxious Arousal subscale consists of 17-items with lower scores indicating better outcomes (range = 17 - 85). The Anhedonic Depression subscale consists of 22-items with lower scores indicating better outcomes (range = 22 - 110).

  6. Self-Help Scale [Assess change from baseline to 2-week and 1-month follow-up]

    The Self-Help Scale asks participants to indicate whether they would be willing to try each of 10 strategies to help deal with depression and anxiety on a 5-point Likert-type scale from 0 (definitely not) to 4 (extremely willing). Higher scores indicate a better outcome (range = 0 - 40).

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Low distress tolerance defined as a DTS mean score of 2.56 or lower

  • Daily smoking for at least one year (minimum 5 cigarettes per day and biochemically confirmed via Carbon Monoxide [CO] analysis at least 5 ppm)

Exclusion Criteria:
  • Currently engaging in treatment for an alcohol/drug problem including smoking cessation

  • Active Suicidality

  • Psychosis

  • Legal status that will interfere with participating

  • Not being fluent in English

Contacts and Locations

Locations

Site City State Country Postal Code
1 Anxiety and Health Research Laboratory and Substance Use Treatment Clinic, University of Houston Houston Texas United States 77204

Sponsors and Collaborators

  • University of Houston
  • National Institute on Drug Abuse (NIDA)

Investigators

  • Principal Investigator: Brooke Kauffman, M.A., University of Houston
  • Principal Investigator: Michael Zvolensky, Ph.D., University of Houston

Study Documents (Full-Text)

More Information

Publications

None provided.
Responsible Party:
Brooke Kauffman, Principal Investigator, University of Houston
ClinicalTrials.gov Identifier:
NCT03918031
Other Study ID Numbers:
  • STUDY00000686
  • 1F31DA046127-01
First Posted:
Apr 17, 2019
Last Update Posted:
Nov 1, 2021
Last Verified:
Oct 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Brooke Kauffman, Principal Investigator, University of Houston
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 1, 2021